Expression of matrix metalloproteinases and their inhibitors in human trabecular meshwork cells

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 8, 2003, Pages 3485-3493

  Pang, Iok Hou ^a   Hellberg, Peggy E ^b   Fleenor, Debra L ^b   Jacobson, Nasreen ^b   Clark, Abbot F ^b  

^a ALCON RESEARCH LTD   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; INTERLEUKIN 1ALPHA; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; PLATELET DERIVED GROWTH FACTOR BB; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

AQUEOUS HUMOR OUTFLOW; ARTICLE; CELL STRAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK; ZYMOGRAPHY;

ADOLESCENT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFANT; INTERLEUKIN-1; MATRIX METALLOPROTEINASES; MIDDLE AGED; PLATELET-DERIVED GROWTH FACTOR; TETRADECANOYLPHORBOL ACETATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRABECULAR MESHWORK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0041364481     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0756     Document Type: Article

References (45)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393.
2. Segawa K. Electron microscopic changes in the trabecular tissue in primary open angle glaucoma. In: Bellows JG, ed. Glaucoma: Contemporary International Concepts. New York: Masson Publishing; 1979;17-23.
3. Rohen JW, Linner E, Witmer R. Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma. Exp Eye Res. 1973;17:19-31.
4. Lütjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW. Quantitative analysis of "plaque material" between ciliary muscle tips in normal and glaucomatous eyes. Exp Eye Res. 1986;42:457-465.
5. Rohen JW, Lütjen-Drecoll E, Flügel C, Meyer M, Grierson I. Ultrastructure of the trabecular meshwork in untreated cases of primary. open-angle glaucoma (POAG). Exp Eye Res. 1993;56:683-692.
6. Knepper PA, Goossens W, Hvizd M, Palmberg PF. Glycosaminoglycans of the human trabecular meshwork in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 1996;37:1360-1367.
7. Acott TS, Kingsley PD, Samples JR, Van Buskirk EM. Human trabecular meshwork organ culture: morphology and glycosaminoglycan synthesis. Invest Ophthalmol Vis Sci. 1988;29:90-100.
8. Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32:172-180.
9. Acott TS. Trabecular extracellular matrix regulation. In: Drance SM, Van Buskirk EM, Neufeld AH, eds. Pharmacology of Glaucoma. Baltimore: Williams & Wilkins; 1992:125-127.
10. Samples JR, Alexander JP, Acott TS. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone. Invest Ophthalmol Vis Sci. 1993; 34:3386-3395.
11. Baramova E, Foidart J-M. Matrix metalloproteinase family. Cell Biol Int. 1995;19:239-242.
12. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 1998;21:75-80.
13. Clark AF. New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Invest Ophthalmol Vis Sci. 1998;39:2514-2516.
14. Lukes A, Mun Bryce S, Lukes M, Rosenberg GA. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol. 1999;19:267-284.
15. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
16. Parshley DE, Bradley JM, Samples JR, Van Buskirk EM, Acott TS. Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork. Curr Eye Res. 1995;14:537-544.
17. Parshley DE, Bradley JM, Fisk A, et al. Laser trabeculoplasty induces stromelysin expression by trabecular juxtacanalicular cells. Invest Ophthalmol Vis Sci. 1996;37:795-804.
18. Alexander JP, Samples JR, Acott TS. Growth factor and cytokine modulation of trabecular meshwork matrix metalloproteinase and TIMP expression. Curr Eye Res. 1998;17:276-285.
19. Jacobson N, Andrews M, Shepard AR, et al. Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor. Hum Mol Genet. 2001;10:117-125.
20. Wordinger RJ, Lambert W, Agarwal R, Talati M, Clark AF. Human trabecular meshwork cells secrete neurotrophins and express neurotrophin receptors (Trk). Invest Ophthalmol Vis Sci. 2000;41:3833-3841.
21. Steely HT Jr, English Wright SL, Clark AF. The similarity of protein expression in trabecular meshwork and lamina cribrosa: implications for glaucoma. Exp Eye Res. 2000;70:17-30.
22. Steely HT, Browder SL, Julian MB, Miggans ST, Wilson KL, Clark AF. The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1992;33:2242-2250.
23. Wilson K, McCartney MD, Miggans ST, Clark AF. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr Eye Res. 1993;12:783-793.
24. Clark AF, Wilson K, McCartney MD, Miggans ST, Kunkle M, Howe W. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1994;35:281-294.
25. Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW. Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. Curr Eye Res. 1995;14:611-617.
26. Okada Y, Harris ED, Nagase H. The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts: purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem J. 1988;254:731-741.
27. Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996;15:869-875.
28. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997;38:2214-2223.
29. Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997; 38:2772-2780.
30. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase; a study with natural and recombinant enzymes. Biochem J. 1987;248:265-268.
31. Salamonsen LA, Nagase H, Woolley DE. Production of matrix metalloproteinase 3 (stromelysin) by cultured ovine endometrial cells. J Cell Sci. 1991;100:381-385.
32. Di Girolamo N, Lloyd A, McCluskey P, Filipic M, Wakefield D. Increased expression of matrix metalloproteinases in vivo and scleritis tissue and in vitro in cultured human scleral fibroblasts. Am J Pathol. 1997;150:653-666.
33. Yee J, Kuncio GS, Bhandari B, Shihab FS, Neilson EG. Identification of promoter activity and differential expression of transcripts encoding the murine stromelysin-1 gene in renal cells. Kidney Int. 1997;52:120-129.
34. Matrisian L. The matrix-degrading metalloproteinases. Bioessays. 1992;14:455-463.
35. Alexander CM, Werb Z. Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol. 1989;1:974-982.
36. Murphy G, Nagase H, Brinckerhoff CE. Relationship of procollagenase activator, stromelysin and matrix metalloproteinase 3. Coll Relat Res. 1988;8:389-391.
37. Welgus HG. Stromelysin: structure and function. Agents Actions Suppl. 1991;35:61-67.
38. Fleenor DL, Pang I-H, Clark AF. Involvement of AP-1 in interleukin-1α-stimulated MMP-3 expression in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2003;44:3494-3501.
39. Kee C, Seo K. The effect of interleukin-1alpha on outflow facility in rat eyes. J Glaucoma. 1997;6:246-249.
40. Bradley JM, Anderssohn AM, Colvis CM, et al. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalpha. Invest Ophthalmol Vis Sci. 2000;41:422-430.
41. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Surv Ophthalmol. 1997; 41(suppl 2):S53-S59.
42. Lütjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res. 1988;47:761-769.
43. Lütjen-Drecoll E, Tamm E. The effects of ocular hypotensive doses of PGF2 alpha-isopropylester on anterior segment morphology. Prog Clin Biol Res. 1989;312:437-446.
44. Tamm E, Lütjen-Drecoll E, Rohen JW. Age-related changes of the ciliary muscle in comparison with changes induced by treatment with prostaglandin F2 alpha: an ultrastructural study in rhesus and cynomolgus monkeys. Mech Ageing Dev. 1990;51:101-120.
45. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389-402.